Cargando…

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

Detalles Bibliográficos
Autores principales:	Kaloyannidis, Panayotis, Shaibani, Eshrak Al, Apostolidis, Ioannis, Kanfar, Solaf, Anezi, Khalid Al, Hashmi, Hani Al
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760676/ https://www.ncbi.nlm.nih.gov/pubmed/30337698 http://dx.doi.org/10.1038/s41409-018-0362-7

Ejemplares similares

Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach
por: Kaloyannidis, Panayotis, et al.
Publicado: (2021)

De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Single-Agent High-Dose Melphalan as Conditioning Regimen in Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma: Safety, and Long-Term Efficacy
por: Al Hashmi, Hani, et al.
Publicado: (2018)

ANTIBODY RESPONSES AND SAFETY OF THE COMMERCIALLY AVAILABLE VACCINES AGAINST SARS-COV-2 VIRUS IN ALLOGRAFTED PATIENTS: REAL WORLD DATA FROM A SINGLE CENTER
por: Kaloyannidis, Panayotis, et al.
Publicado: (2022)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??
por: Kaloyannidis, Panayotis, et al.
Publicado: (2022)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Hengwei, et al.
Publicado: (2021)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
por: Hinterlang, Mélanie, et al.
Publicado: (2022)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
por: D’Alessio, A., et al.
Publicado: (2020)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies
por: Zhang, Meng-yun, et al.
Publicado: (2022)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2020)

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2021)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
por: Al Sharie, Ahmed H., et al.
Publicado: (2023)

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
por: Ong, Jian Chun Matthew, et al.
Publicado: (2023)

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY
por: Locatelli, Franco, et al.
Publicado: (2023)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

Establishing hematopoietic stem cell transplant programs; overcoming cost through collaboration
por: Al-Hashmi, Hani, et al.
Publicado: (2020)

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL
por: Jaramillo, Sonia, et al.
Publicado: (2020)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
por: Pope, Eleanor, et al.
Publicado: (2022)

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
por: Fogelman, David, et al.
Publicado: (2018)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East
por: El Fakih, Riad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ld1f07mq7d1t92v6635jvnvi8